• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Trends in Lipoprotein(a) Testing at the University of Pennsylvania Health Systems from 2012-2021
Lipoprotein(a) [Lp(a)] is an independent and causal risk factor for atherosclerotic cardiovascular disease (ASCVD). Elevated Lp(a) levels are associated with a higher risk for myocardial infarction, coronary artery disease, aortic stenosis, and stroke. Lp(a) levels are primarily genetically driven and minimally impacted by diet and lifestyle, so a single measurement can identify individuals with elevated levels. However, Lp(a) screening has not been widely integrated into clinical practice in the United States.
Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Archna Bajaj, Lakshmi Parvathinathan, Marjorie Risman, Ahmad Alsattari, Daniel J. Rader Tags: Best Practices in Lipid Management Source Type: research

Five Ways To Improve Your Mental Health In 2020
(CNN) — It’s a difficult birth for this new decade. The year 2020 kicks off under the shadow of divisive politics, international security threats, a spate of hate crimes, and a planet in environmental peril, plus all the reasons we’re stressed individually: work, health problems, life changes and more. No wonder so many of us are anxious or depressed. But you can take scientifically validated steps to improve your mental outlook, and — because the mind and body are entwined — these behaviors also will improve your overall health. 1. Practice optimism The studies are positive: Looking on the br...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 4, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health CNN Mental Health Source Type: news

EuroPCR 2018 Roundup: Medtronic touts BP reductions, no major adverse events in renal denervation trial
Medtronic (NYSE:MDT) today released six-month results from a trial of its Symplicity Spyral renal denervation system exploring its use treating hypertensive patients who are already taking anti-hypertension medications, touting significant reductions in blood pressure and no major adverse safety events. Results were presented at the 2018 EuroPCR annual meeting in Paris and were published in The Lancet. In the trial, patients were prescribed up to three anti-hypertensive medications, including diuretics, calcium channel blockers, ACE/ARB inhibitors or beta blockers, the Fridley, Minn.-based company said. Patients were then...
Source: Mass Device - May 23, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Cardiac Implants Cardiovascular Clinical Trials Abbott Medtronic ReCor Medical Source Type: news

Insurance company requirements place heavy administrative burden on physicians seeking to prescribe new cholesterol-lowering drugs
(University of Pennsylvania School of Medicine) A rare glimpse into the prior authorization requirements implemented by public and private insurance providers across the country has found substantial administrative burden for a new class of medications for patients with high cholesterol that places them at high risk for heart attack or stroke, according to new research.
Source: EurekAlert! - Medicine and Health - January 16, 2018 Category: International Medicine & Public Health Source Type: news

Medtronic readies pivotal trial in renal denervation
Medtronic (NYSE:MDT) said today that it’s ready for a run at FDA approval for renal denervation in treating high blood pressure, more than three years after the failure of a high-profile clinical trial. Back in January 2014, Fridley, Minn.-based Medtronic shocked medtech when it announced that the highly anticipated Symplicity HTN-3 trial, examining ablation of the around the renal arteries in treating hypertension, failed to meet its efficacy endpoint. The company suspended enrollment in its other Symplicity trials around the world and later took a $200 million write-down on its renal denervation assets. News of th...
Source: Mass Device - August 28, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Wall Street Beat Medtronic Renal Source Type: news

Increased cardiovascular risk in men using testosterone therapy prompts warning
(University of Pennsylvania School of Medicine) Men taking testosterone therapy had a 29 percent greater risk of death, heart attack and stroke according to a study of a "real world" population of men. An accompanying editorial in JAMA by an endocrinologist with the Perelman School of Medicine at the University of Pennsylvania notes that the mounting evidence of a signal of cardiovascular risk warrants cautious testosterone prescribing and additional investigation.
Source: EurekAlert! - Social and Behavioral Science - November 5, 2013 Category: Global & Universal Source Type: news

Minimally invasive approach provides at least equivalent results for surgical correction of mitral regurgitation: A propensity-matched comparison
Conclusions: In appropriate patients with isolated mitral valve disease of any cause, a right minithoracotomy approach may be used without compromising clinical outcome.
Source: The Journal of Thoracic and Cardiovascular Surgery - February 16, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Andrew B. Goldstone, Pavan Atluri, Wilson Y. Szeto, Alen Trubelja, Jessica L. Howard, John W. MacArthur, Craig Newcomb, Joseph P. Donnelly, Dale M. Kobrin, Mary A. Sheridan, Christiana Powers, Robert C. Gorman, Joseph H. Gorman, Alberto Pochettino, Joseph Tags: Acquired Cardiovascular Disease Source Type: research